Oral Session 2-8A Transplant for acule leukemia

[OS2-8A-2] Allogeneic HCT in patients with untreated acute myeloid leukemia: KSGCT multicenter analysis

Takayoshi Tachibana¹, Takuma Ishizaki², Satoshi Takahashi³, Noriko Doki⁴, Shun-Ichi Kimura⁵, Emiko Sakaida⁶, Makoto Onizuka⁷, Takehiko Mori⁸, Shin Fujisawa⁹, Shin-Ichiro Fujiwara¹⁰, Takeshi Saito¹¹, Maki Hagihara¹², Nobuyuki Aotsuka¹³, Moritaka Gotoh¹⁴, Kensuke Usuki¹⁵, Nobuhiro Tsukada¹⁶, Yoshinobu Kanda^5,10, Heiwa Kanamori¹, Shinichiro Okamoto⁸ (1.Dep. Hematology, Kanagawa Cancer Center, Yokohama, Japan, 2.Dep. Medicine and Clinical Science, Gunma University, Maebashi, Japan, 3.Dep. Hematology/Oncology, The Institute of Medical Science, Tokyo Univ., 4.Hematology Division, Tokyo Metropolitan Komagome Hospital, Tokyo, Japan, 5.Div. Hematology, Saitama Medical Center, Jichi Medical University, Saitama, Japan, 6.Department of Hematology, Chiba University Hospital, Chiba, Japan, 7.Dep. Hematology/Oncology, Tokai University, Isehara, Japan, 8.Div. Hematology, Dep. Medicine, Keio University, Tokyo, Japan, 9.Dep. Hematology, Yokohama City University Medical Center, Yokohama, Japan, 10.Div. Hematology, Department of Medicine, Jichi Medical University, Shimotsuke, Japan, 11.Div. Clinical Oncology/Hematology, Jikei University, Tokyo, Japan, 12.Dep. Hematology and Clinical Immunology, Yokohama City University, Yokohama, Japan, 13.Div. Hematology/Oncology, Japanese Red Cross Society Narita Hospital, Narita, Japan, 14.First Department of Internal Medicine, Tokyo Medical University,Tokyo, Japan, 15.Department of Hematology, NTT Medical Center Tokyo, Tokyo, Japan, 16.Dep. Hematology, Japanese Red Cross Medical Center, Tokyo, Japan)